Last June, Patricia Hart — now 59 years — heard words no one wants to hear: triple-negative invasive ductal carcinoma. Her care team was frank about the danger: This form of breast cancer is ...
Potential biomarker of PD-L1 expression phenotypes in tumor and immune cells for combined PD-1 and CTLA-4 blockade therapies in advanced NSCLC. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Real-world biomarker testing patterns, first line treatment and drivers of treatment choice in patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma in the United States ...
Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback